Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma

Inclusion Criteria: * Histologically confirmed primary CNS lymphoma. * Newly diagnosed. * ECOG (Eastern Cooperative Oncology Group) Performance status of 0-1. * Relevant hospital examination including laboratory examination and physical examination (Chest X-ray, electrocardiogram, abdomen B ultrasonography, magnetic resonance imaging (MRI) of head and neck) must to be done, in order to exclude other system fatal diseases. * Must have adequate organ function as defined by the protocol: Adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min; Adequate hepatic function: bilirubin level ≤ 1.5 x ULN, ASAT \& ALST ≤ 1.5 x ULN.Adequate bone marrow reserves: neutrophil (ANC) count ≥ 1500 /mm\^3, platelet count ≥ 100,000 /mm\^3, hemoglobin ≥ 9 g/dl. * Age \>/= 18 and \</= 75 years * Signed written informed consent prior to study entry. Exclusion Criteria: * Patients with human immunodeficiency virus seropositivity and systemic lymphoma manifestation. * Serious uncontrolled concurrent illness. * Previous brain radiotherapy, systemic chemotherapy. * Concurrent chronic systemic immune therapy, targeted therapy not indicated in this study protocol. * Any evidence of prior exposure to Hepatitis B virus. * Unable to comprehend the study requirements or who are not likely to comply with the study parameters. * Pregnant (confirmed by serum or urine β-HCG) or lactating.